by Scott Larrivee | Sep 15, 2023 | News
Executive with three decades of successful multinational operations and commercial experience to lead launch of proprietary radioisotope production platform VALENCIA, Calif. – Sept. 15, 2023 – Nusano, Inc., a company reshaping the production of cancer-fighting...
by Scott Larrivee | Sep 12, 2023 | Industry News
News from the United Kingdom’s Institute of Cancer Research (ICR) published in The Lancet Oncology reports that targeted radiation treatment is “greatly improving” the quality of life for cancer patients. ICR writes: Patients with advanced prostate...
by Scott Larrivee | Aug 22, 2023 | News
With many now expecting radiopharmaceuticals to grow into a $20-30 billion market, investors are increasingly looking at the obstacles and opportunities for suppliers and drugmakers in this space. To advance these discussions, on Friday, May 12, 2023, Nusano and...
by Scott Larrivee | Jul 20, 2023 | News
VALENCIA, Calif. – July 20, 2023 – Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, today announced participation in two conferences in July 2023. Nusano CEO Chris Lowe will present an overview of the company’s...
by Scott Larrivee | May 15, 2023 | News, Utah
SALT LAKE CITY and BOCA RATON, Fla. – May 15, 2023 – Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, and PharmaLogic, a world-class contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals,...
